You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBosutinib
Accession NumberDB06616
TypeSmall Molecule
GroupsApproved
DescriptionBosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.
Structure
Thumb
Synonyms
4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile
Bosulif®
Bosutinib
Bosutinib Monohydrate
SKI 606
SKI-606
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BosulifTablet, film coated100 mg/1OralU.S. Pharmaceuticals2012-09-04Not applicableUs
BosulifTablet, film coated500 mg/1OralPfizer Laboratories Div Pfizer Inc2012-09-04Not applicableUs
BosulifTablet100 mgOralPfizer Canada Inc2014-04-24Not applicableCanada
BosulifTablet500 mgOralPfizer Canada Inc2014-03-24Not applicableCanada
BosulifTablet, film coated100 mg/1OralPfizer Laboratories Div Pfizer Inc2012-09-04Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5018V4AEZ0
CAS number380843-75-4
WeightAverage: 530.446
Monoisotopic: 529.164745233
Chemical FormulaC26H29Cl2N5O3
InChI KeyUBPYILGKFZZVDX-UHFFFAOYSA-N
InChI
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
IUPAC Name
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
SMILES
COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl
Pharmacology
IndicationTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionBosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Breakpoint cluster region proteinProteinyes
inhibitor
HumanP11274 details
Tyrosine-protein kinase ABL1Proteinyes
inhibitor
HumanP00519 details
Tyrosine-protein kinase LynProteinunknownNot AvailableHumanP07948 details
Tyrosine-protein kinase HCKProteinunknown
inhibitor
HumanP08631 details
Proto-oncogene tyrosine-protein kinase SrcProteinunknown
inhibitor
HumanP12931 details
Cyclin-dependent kinase 2Proteinunknown
inhibitor
HumanP24941 details
Dual specificity mitogen-activated protein kinase kinase 1Proteinunknown
inhibitor
HumanQ02750 details
Dual specificity mitogen-activated protein kinase kinase 2Proteinunknown
inhibitor
HumanP36507 details
Mitogen-activated protein kinase kinase kinase 2Proteinunknown
inhibitor
HumanQ9Y2U5 details
Calcium/calmodulin-dependent protein kinase type II subunit gammaProteinunknown
inhibitor
HumanQ13555 details
Related Articles
AbsorptionFood increase the exposure of bosutinib. Tmax, single dose, cancer patients, fed-state = 4-6 hours; After 15 daily doses of bosutinib 500 mg with food in CML patients, the pharmacokinetic parameters are as follows: Cmax = 200 ng/mL; AUC = 3650 ng∙h/mL
Volume of distribution

Apparent volume of distribution = 6080 ± 1230 L.

Protein binding94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent.
Metabolism

Bosutinib is primarily metabolized by CYP3A4. The major circulating metabolites identified in plasma are oxydechlorinated (M2) bosutinib (19% of parent exposure) and N-desmethylated (M5) bosutinib (25% of parent exposure), with bosutinib N-oxide (M6) as a minor circulating metabolite. All the metabolites were deemed inactive.

Route of eliminationWhen given a single oral dose, 91.3% of the dose was recovered in feces and 3% of the dose recovered in urine.
Half lifeTerminal phase elimination half-life, single oral dose, fed-state = 22.5 hours
Clearance

Mean clearance (CL/F), single oral dose, fed-state = 189 L/h

ToxicityMost common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue. Because bosutinib is not an inhibitor of c-KIT or PDGF receptor, it has less hematologic toxicities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Bosutinib.Approved
AcetaminophenThe serum concentration of Bosutinib can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Bosutinib.Approved, Vet Approved
AfatinibThe serum concentration of Bosutinib can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Bosutinib can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Bosutinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Bosutinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Bosutinib can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bosutinib.Approved, Investigational
Aluminum hydroxideThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Bosutinib can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Bosutinib.Approved, Investigational
Aminohippuric acidThe serum concentration of Bosutinib can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Bosutinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Bosutinib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Bosutinib can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Bosutinib can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Bosutinib can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Bosutinib.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Bosutinib.Approved
AprepitantThe serum concentration of Bosutinib can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Bosutinib.Approved, Investigational
AsenapineThe serum concentration of Bosutinib can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Bosutinib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Bosutinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Bosutinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Bosutinib can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bosutinib.Approved, Investigational
AzelastineThe serum concentration of Bosutinib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Bosutinib can be increased when it is combined with Azithromycin.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Bosutinib.Investigational
BenzocaineThe serum concentration of Bosutinib can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bosutinib.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Bosutinib.Approved, Investigational
BexaroteneThe serum concentration of Bosutinib can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Bosutinib can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Bosutinib can be decreased when it is combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Bosutinib can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Bosutinib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosutinib can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Bosutinib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Bosutinib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Bosutinib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Bosutinib can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Bosutinib can be increased when it is combined with Caffeine.Approved
Calcium carbonateThe serum concentration of Bosutinib can be decreased when it is combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bosutinib.Experimental
CanagliflozinThe serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Bosutinib can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Bosutinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Bosutinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bosutinib.Approved
CarvedilolThe serum concentration of Bosutinib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Bosutinib can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Bosutinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bosutinib.Withdrawn
ChloroquineThe serum concentration of Bosutinib can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Bosutinib can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Bosutinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Bosutinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Bosutinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Bosutinib can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Bosutinib can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Bosutinib can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Bosutinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bosutinib.Approved
CitalopramThe serum concentration of Bosutinib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Bosutinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Bosutinib can be increased when it is combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bosutinib.Approved, Illicit
ClofazimineThe serum concentration of Bosutinib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Bosutinib.Approved, Investigational
ClomipramineThe serum concentration of Bosutinib can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Bosutinib.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Bosutinib.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Bosutinib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bosutinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Bosutinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bosutinib.Approved
ColchicineThe serum concentration of Bosutinib can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Bosutinib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Bosutinib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bosutinib.Approved
CrizotinibThe serum concentration of Bosutinib can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Bosutinib can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib.Approved
DabrafenibThe serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Bosutinib can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Bosutinib can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bosutinib.Approved
DarunavirThe serum concentration of Bosutinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Bosutinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Bosutinib can be increased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Bosutinib.Approved
DeferasiroxThe serum concentration of Bosutinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Bosutinib can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Bosutinib can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bosutinib.Approved
DesloratadineThe serum concentration of Bosutinib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Bosutinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Bosutinib can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bosutinib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Bosutinib can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bosutinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved
DigoxinThe serum concentration of Bosutinib can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Bosutinib can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Bosutinib.Illicit
DiltiazemThe serum concentration of Bosutinib can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Bosutinib can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bosutinib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bosutinib.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Bosutinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Bosutinib can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Bosutinib can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Bosutinib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Bosutinib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Bosutinib can be increased when it is combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bosutinib.Approved
EfavirenzThe serum concentration of Bosutinib can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Bosutinib can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Bosutinib.Approved, Investigational
EnalaprilThe serum concentration of Bosutinib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Bosutinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Bosutinib can be decreased when it is combined with Epinastine.Approved, Investigational
ErgonovineThe serum concentration of Bosutinib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Bosutinib can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Bosutinib.Approved, Investigational
ErythromycinThe serum concentration of Bosutinib can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Bosutinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Bosutinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bosutinib.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Bosutinib can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Bosutinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Bosutinib can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bosutinib.Approved
EtoposideThe serum concentration of Bosutinib can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Bosutinib can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bosutinib.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bosutinib.Approved
FamotidineThe serum concentration of Bosutinib can be decreased when it is combined with Famotidine.Approved
FelodipineThe serum concentration of Bosutinib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Bosutinib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bosutinib.Approved
FexofenadineThe serum concentration of Bosutinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Bosutinib can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Bosutinib can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Bosutinib can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Bosutinib can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Bosutinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Bosutinib can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bosutinib.Approved
FluvoxamineThe serum concentration of Bosutinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Bosutinib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bosutinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Bosutinib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Bosutinib can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Bosutinib can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Bosutinib.Approved
GenisteinThe serum concentration of Bosutinib can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Bosutinib can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Bosutinib can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Bosutinib can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bosutinib.Approved
GrepafloxacinThe serum concentration of Bosutinib can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Bosutinib can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Bosutinib.Approved
IdelalisibThe serum concentration of Bosutinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Bosutinib can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Bosutinib can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Bosutinib.Approved
IndinavirThe serum concentration of Bosutinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Bosutinib can be increased when it is combined with Indomethacin.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bosutinib.Approved, Investigational
IsavuconazoniumThe serum concentration of Bosutinib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Bosutinib can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Bosutinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bosutinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Bosutinib can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Bosutinib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bosutinib.Approved
KetoconazoleThe serum concentration of Bosutinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bosutinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bosutinib.Approved, Investigational
LansoprazoleThe serum concentration of Bosutinib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Bosutinib can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bosutinib.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bosutinib.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Bosutinib.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bosutinib.Approved, Investigational
LevofloxacinThe serum concentration of Bosutinib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Bosutinib.Approved
LevothyroxineThe serum concentration of Bosutinib can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Bosutinib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Bosutinib.Approved
LiothyronineThe serum concentration of Bosutinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Bosutinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Bosutinib can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Bosutinib can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Bosutinib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Bosutinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Bosutinib can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Bosutinib can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Bosutinib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Bosutinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bosutinib can be decreased when it is combined with Lumacaftor.Approved
MagaldrateThe serum concentration of Bosutinib can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium Trisilicate.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Bosutinib.Approved, Investigational
MaprotilineThe serum concentration of Bosutinib can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Bosutinib can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Bosutinib can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Bosutinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Bosutinib can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bosutinib.Withdrawn
MethadoneThe serum concentration of Bosutinib can be increased when it is combined with Methadone.Approved
MethanthelineThe serum concentration of Bosutinib can be decreased when it is combined with Methantheline.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bosutinib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bosutinib.Approved, Vet Approved
MetiamideThe serum concentration of Bosutinib can be decreased when it is combined with Metiamide.Experimental
MetoprololThe serum concentration of Bosutinib can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Bosutinib can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Bosutinib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Bosutinib can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Bosutinib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Bosutinib.Approved
MitomycinThe serum concentration of Bosutinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Bosutinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Bosutinib can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Bosutinib can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Bosutinib can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bosutinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Bosutinib.Approved
NafcillinThe serum concentration of Bosutinib can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bosutinib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Bosutinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Bosutinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Bosutinib can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Bosutinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Bosutinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Bosutinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Bosutinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Bosutinib can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Bosutinib can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Bosutinib can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Bosutinib can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bosutinib.Approved
NisoldipineThe serum concentration of Bosutinib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Bosutinib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Bosutinib can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe serum concentration of Bosutinib can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Bosutinib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Bosutinib can be increased when it is combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bosutinib.Approved
OmeprazoleThe serum concentration of Bosutinib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Bosutinib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Bosutinib.Approved
P-NitrophenolThe serum concentration of Bosutinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Bosutinib can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bosutinib can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Bosutinib can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Bosutinib.Approved, Investigational
PantoprazoleThe serum concentration of Bosutinib can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Bosutinib can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bosutinib.Approved
PentobarbitalThe serum concentration of Bosutinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Bosutinib can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Bosutinib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Bosutinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Bosutinib can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bosutinib.Approved
Platelet Activating FactorThe serum concentration of Bosutinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bosutinib.Approved
PonatinibThe serum concentration of Bosutinib can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Bosutinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Bosutinib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Bosutinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bosutinib.Approved, Vet Approved
PrednisoneThe serum concentration of Bosutinib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Bosutinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Bosutinib can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Bosutinib can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Bosutinib can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Bosutinib can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Bosutinib can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Bosutinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bosutinib.Approved
QuercetinThe serum concentration of Bosutinib can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Bosutinib.Approved
QuinacrineThe serum concentration of Bosutinib can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Bosutinib can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Bosutinib can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Bosutinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Bosutinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Bosutinib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Bosutinib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Bosutinib can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Bosutinib can be increased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Bosutinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Bosutinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bosutinib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bosutinib.Approved, Investigational
RilpivirineThe serum concentration of Bosutinib can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Bosutinib.Approved, Investigational
RitonavirThe serum concentration of Bosutinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Bosutinib.Approved
RolapitantThe serum concentration of Bosutinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Bosutinib.Approved, Investigational
Roxatidine acetateThe serum concentration of Bosutinib can be decreased when it is combined with Roxatidine acetate.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Bosutinib.Approved, Vet Approved
SaquinavirThe serum concentration of Bosutinib can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Bosutinib can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Bosutinib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Bosutinib.Approved
SertralineThe serum concentration of Bosutinib can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Bosutinib can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bosutinib.Approved
SiltuximabThe serum concentration of Bosutinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bosutinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Bosutinib can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Bosutinib can be increased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Bosutinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bosutinib.Approved
SorafenibThe serum concentration of Bosutinib can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Bosutinib.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bosutinib.Experimental
SpironolactoneThe serum concentration of Bosutinib can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Bosutinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Bosutinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Bosutinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Bosutinib can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Bosutinib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Bosutinib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Bosutinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Bosutinib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Bosutinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Bosutinib can be increased when it is combined with Tacrolimus.Approved, Investigational
TAK-390MRThe serum concentration of Bosutinib can be decreased when it is combined with TAK-390MR.Investigational
TamoxifenThe serum concentration of Bosutinib can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Bosutinib can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bosutinib.Approved
TelaprevirThe serum concentration of Bosutinib can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Bosutinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Bosutinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Bosutinib can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Bosutinib can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Bosutinib can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Bosutinib can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Bosutinib can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Bosutinib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Bosutinib can be increased when it is combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Bosutinib.Approved
TocilizumabThe serum concentration of Bosutinib can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Bosutinib can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bosutinib.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Bosutinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bosutinib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bosutinib.Approved
TrazodoneThe serum concentration of Bosutinib can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Bosutinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Bosutinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Bosutinib can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Bosutinib can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Bosutinib can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bosutinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bosutinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Bosutinib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Bosutinib.Approved
VenlafaxineThe serum concentration of Bosutinib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Bosutinib can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bosutinib.Approved, Investigational
VinorelbineThe serum concentration of Bosutinib can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bosutinib.Approved
VoriconazoleThe serum concentration of Bosutinib can be increased when it is combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bosutinib.Approved
ZimelidineThe serum concentration of Bosutinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Bosutinib can be increased when it is combined with Ziprasidone.Approved
Food Interactions
  • When given with a high fat meal, the Cmax and AUC of bosutinib increased 1.8- and 1.7-fold, respectively.
References
Synthesis ReferenceNot Available
General References
  1. Amsberg GK, Schafhausen P: Bosutinib in the management of chronic myelogenous leukemia. Biologics. 2013;7:115-22. doi: 10.2147/BTT.S30182. Epub 2013 May 6. [PubMed:23674887 ]
  2. Keller-V Amsberg G, Brummendorf TH: Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2012 Sep;12(9):1121-7. doi: 10.1586/era.12.84. [PubMed:23098112 ]
  3. Link [Link]
External Links
ATC CodesL01XE14
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (326 KB)
MSDSDownload (97.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9823
Blood Brain Barrier+0.9272
Caco-2 permeable+0.6542
P-glycoprotein substrateSubstrate0.7601
P-glycoprotein inhibitor IInhibitor0.8409
P-glycoprotein inhibitor IIInhibitor0.9108
Renal organic cation transporterInhibitor0.5663
CYP450 2C9 substrateNon-substrate0.854
CYP450 2D6 substrateNon-substrate0.6953
CYP450 3A4 substrateSubstrate0.6987
CYP450 1A2 substrateInhibitor0.5606
CYP450 2C9 inhibitorNon-inhibitor0.7372
CYP450 2D6 inhibitorNon-inhibitor0.5136
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7021
Ames testAMES toxic0.5922
CarcinogenicityNon-carcinogens0.8869
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4201 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6147
hERG inhibition (predictor II)Inhibitor0.7754
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral500 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral500 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6002008 No1998-03-272018-03-27Us
US7417148 No2006-01-232026-01-23Us
US7767678 No2006-11-232026-11-23Us
US7919625 No2005-12-112025-12-11Us
USRE42376 No1999-09-242019-09-24Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0095 mg/mLALOGPS
logP4.87ALOGPS
logP4.09ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)15.48ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area82.88 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity142.12 m3·mol-1ChemAxon
Polarizability56.14 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassAminoquinolines and derivatives
Direct ParentAminoquinolines and derivatives
Alternative Parents
Substituents
  • Hydroxyquinoline
  • Aminoquinoline
  • Methoxyaniline
  • Methoxybenzene
  • Substituted aniline
  • Phenol ether
  • 1,3-dichlorobenzene
  • Anisole
  • N-alkylpiperazine
  • N-methylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Aminopyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Nitrile
  • Carbonitrile
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rho guanyl-nucleotide exchange factor activity
Specific Function:
GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.
Gene Name:
BCR
Uniprot ID:
P11274
Molecular Weight:
142818.07 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending ...
Gene Name:
LYN
Uniprot ID:
P07948
Molecular Weight:
58573.595 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immuno...
Gene Name:
HCK
Uniprot ID:
P08631
Molecular Weight:
59599.355 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Molecular Weight:
59834.295 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synt...
Gene Name:
CDK2
Uniprot ID:
P24941
Molecular Weight:
33929.215 Da
References
  1. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. [PubMed:19039322 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Receptor signaling protein tyrosine phosphatase activity
Specific Function:
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2...
Gene Name:
MAP2K1
Uniprot ID:
Q02750
Molecular Weight:
43438.65 Da
References
  1. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. [PubMed:19039322 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).
Gene Name:
MAP2K2
Uniprot ID:
P36507
Molecular Weight:
44423.735 Da
References
  1. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. [PubMed:19039322 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Component of a protein kinase signal transduction cascade. Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7 (By similarity). Plays a role in caveolae kiss-and-run dynamics.
Gene Name:
MAP3K2
Uniprot ID:
Q9Y2U5
Molecular Weight:
69740.21 Da
References
  1. Ahmad S, Hughes MA, Johnson GL, Scott JE: Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. J Biomol Screen. 2013 Apr;18(4):388-99. doi: 10.1177/1087057112466430. Epub 2012 Nov 7. [PubMed:23134735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in sarcoplsamic reticulum Ca(2+) transport in skeletal muscle and may function in dendritic spine and synapse formation and neuronal plasticity. In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport and in fa...
Gene Name:
CAMK2G
Uniprot ID:
Q13555
Molecular Weight:
62608.655 Da
References
  1. Amsberg GK, Koschmieder S: Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther. 2013;6:99-106. doi: 10.2147/OTT.S19901. Epub 2013 Mar 4. [PubMed:23493838 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:41 / Updated on December 02, 2016 02:44